International Journal of Health and Clinical Research
Yazarlar: Sefali (Sahare) Shinde, Tarani Shinde, Akansha Sahare, Reena Shrivastava, Nilay Shinde
Konular:-
Anahtar Kelimeler:Mifepristone,Fibromyoma,Uterus.
Özet: Background & Method: The present study was carried out as a prospective longitudinal study among patients presenting with confirmed diagnosis of uterine fibroids. A total of 70 women with symptomatic leiomyoma were included in the study. Fibro-myoma patients visited to Obs & Gyn. OPD, BRD Medical College, Gorakhpur in Obs. & Gyn. OPD, BRD Medical College, Gorakhpur from (1st Oct 2016-30th Sept 2016) for duration of 01 year duration. Result: Menstrual blood loss assessment at first visit, one month and 3 month of treatment. At first visit mean PBAC score was 135.17±22.11, at one month mifepristone therapy it was 41.14±45.96 and at 3 months of therapy it was 14.24±31.60,post treatment follow-up after 3 months it was65.98±24.31 .The reduction in PBAC score at the end of 3 months was statistically significant (<0.0001). First visit all patients had menorrhagia at one month of treatment 10(14%) patients had menorrhagia,29(41%) patients had scanty menses ,35% patient have average menses,7% patient had amenorrhea. At 3 month of treatment 77% of patients become amenorrhic,10% had scanty menses,7% had normal menses only 6% had menorrhagia. Conclusion: As seen in present study there was significant reduction in Mean PBAC score by69.6% & 89.5%, mean fibroid volume by 14 % and 38% and mean uterine volume by14 %and 30% while an increase in mean hemoglobin by 9.10 gm/dl to 11.60 gm/dl during mifepristone treatmentat one month and at 3 months of the therapy respectively. , but after stopping treatment there was again increase in Mean PBAC score, mean fibroid volume and mean uterine volume while reduction in mean hemoglobin was seen.As a side effect of mifepristone therapy, endometrial thickness increased by 24.8% at the, simple endometrial hyperplasia in18% without premalignant potential ,7%of patients had increased liver taransaminase(SGPT) all at the end of 03 month therapy mifepristone cannot be concluded as definitive treatment for uterine fibroid. Keywords: Mifepristone, Fibromyoma, Uterus.